-
Je něco špatně v tomto záznamu ?
Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease
T. Tykalova, M. Novotny, E. Ruzicka, P. Dusek, J. Rusz
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
NV19-04-00120
MZ0
CEP - Centrální evidence projektů
NLK
Directory of Open Access Journals
od 2015
PubMed Central
od 2015
Europe PubMed Central
od 2015
Open Access Digital Library
od 2015-04-22
Open Access Digital Library
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2015
Springer Nature OA/Free Journals
od 2015-12-01
Springer Nature - nature.com Journals - Fully Open Access
od 2015-12-01
- Publikační typ
- časopisecké články MeSH
The effect of dopaminergic medication on speech has rarely been examined in early-stage Parkinson's disease (PD) and the respective literature is inconclusive and limited by inappropriate design with lack of PD control group. The study aims to examine the short-term effect of dopaminergic medication on speech in PD using patients with good motor responsiveness to levodopa challenge compared to a control group of PD patients with poor motor responsiveness. A total of 60 early-stage PD patients were investigated before (OFF) and after (ON) acute levodopa challenge and compared to 30 age-matched healthy controls. PD patients were categorised into two clinical subgroups (PD responders vs. PD nonresponders) according to the comparison of their motor performance based on movement disorder society-unified Parkinson's disease rating scale, part III. Seven distinctive parameters of hypokinetic dysarthria were examined using quantitative acoustic analysis. We observed increased monopitch (p > 0.01), aggravated monoloudness (p > 0.05) and longer duration of stop consonants (p > 0.05) in PD compared to healthy controls, confirming the presence of hypokinetic dysarthria in early PD. No speech alterations from OFF to ON state were revealed in any of the two PD groups and speech dimensions investigated including monopitch, monoloudness, imprecise consonants, harsh voice, slow sequential motion rates, articulation rate, or inappropriate silences, although a subgroup of PD responders manifested obvious improvement in motor function after levodopa intake (p > 0.001). Since the short-term usage of levodopa does not easily affect voice and speech performance in PD, speech assessment may provide a medication state-independent motor biomarker of PD.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22009838
- 003
- CZ-PrNML
- 005
- 20220509180334.0
- 007
- ta
- 008
- 220420s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41531-022-00286-y $2 doi
- 035 __
- $a (PubMed)35256614
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Tykalova, Tereza $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic. tykalova.tereza@gmail.com $1 https://orcid.org/0000000311563709
- 245 10
- $a Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease / $c T. Tykalova, M. Novotny, E. Ruzicka, P. Dusek, J. Rusz
- 520 9_
- $a The effect of dopaminergic medication on speech has rarely been examined in early-stage Parkinson's disease (PD) and the respective literature is inconclusive and limited by inappropriate design with lack of PD control group. The study aims to examine the short-term effect of dopaminergic medication on speech in PD using patients with good motor responsiveness to levodopa challenge compared to a control group of PD patients with poor motor responsiveness. A total of 60 early-stage PD patients were investigated before (OFF) and after (ON) acute levodopa challenge and compared to 30 age-matched healthy controls. PD patients were categorised into two clinical subgroups (PD responders vs. PD nonresponders) according to the comparison of their motor performance based on movement disorder society-unified Parkinson's disease rating scale, part III. Seven distinctive parameters of hypokinetic dysarthria were examined using quantitative acoustic analysis. We observed increased monopitch (p > 0.01), aggravated monoloudness (p > 0.05) and longer duration of stop consonants (p > 0.05) in PD compared to healthy controls, confirming the presence of hypokinetic dysarthria in early PD. No speech alterations from OFF to ON state were revealed in any of the two PD groups and speech dimensions investigated including monopitch, monoloudness, imprecise consonants, harsh voice, slow sequential motion rates, articulation rate, or inappropriate silences, although a subgroup of PD responders manifested obvious improvement in motor function after levodopa intake (p > 0.001). Since the short-term usage of levodopa does not easily affect voice and speech performance in PD, speech assessment may provide a medication state-independent motor biomarker of PD.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Novotny, Michal $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic $1 https://orcid.org/0000000156084029 $7 ctu2018985794
- 700 1_
- $a Ruzicka, Evzen $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Dusek, Petr $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Rusz, Jan $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000210363054 $7 xx0093732
- 773 0_
- $w MED00208625 $t NPJ Parkinson's disease $x 2373-8057 $g Roč. 8, č. 1 (2022), s. 22
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220420 $b ABA008
- 991 __
- $a 20220509180332 $b ABA008
- 999 __
- $a ind $b bmc $g 1784407 $s 1161036
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 8 $c 1 $d 22 $e 20220307 $i 2373-8057 $m NPJ Parkinson's disease $n NPJ Parkinsons Dis $x MED00208625
- GRA __
- $a NV19-04-00120 $p MZ0
- LZP __
- $a Pubmed-20220420